Vaishali Pharma (VAISHALI) Q2 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 24/25 earnings summary
20 Nov, 2025Executive summary
Un-audited financial results for the quarter and half year ended September 30, 2024, were approved by the Board and reviewed by statutory auditors with no material misstatements found.
Financial highlights
Revenue from operations for Q2 FY25 was ₹2,078.57 lakhs, up from ₹1,256.56 lakhs in Q2 FY24.
Net profit for Q2 FY25 stood at ₹196.83 lakhs, compared to ₹170.36 lakhs in Q2 FY24.
EPS for the half year ended September 30, 2024, was ₹2.99 (basic), compared to ₹3.10 for the same period last year.
Total comprehensive income for H1 FY25 was ₹366.73 lakhs, up from ₹328.96 lakhs in H1 FY24.
Outlook and guidance
The company continues to operate in a single segment focused on pharmaceutical product sales.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Vaishali Pharma
- Q1 FY27 net profit rose to ₹148.97 lakh standalone, with consolidation of Kesar Pharma boosting group results.VAISHALI
Q1 26/27 - Strong revenue and profit growth, with new associate consolidation and auditor caution on receivables.VAISHALIQ4 25/26
- Q3 FY26 profit rose sequentially, preferential issue to raise ₹12.25 crore approved.VAISHALIQ3 25/26
- Strong revenue and profit growth with improved margins and positive operating cash flow.VAISHALIQ2 25/26
- Q1 FY26 saw higher revenue but lower net profit and EPS amid rising expenses.VAISHALIQ1 25/26
- Revenue and profit rose, but auditor flagged major uncertainty over receivables' recovery.VAISHALIQ4 24/25
- Q1 FY25 saw higher revenue, a return to profit, and increased share capital.VAISHALIQ1 24/25
- Q3 FY25 revenue was flat, but net profit fell on higher costs; auditors found no misstatements.VAISHALIQ3 24/25